Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06910943 · ClinicalTrials.gov registry record · Phase 2
Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support
A Phase 2 study of Liver Injury and Choline Deficiency, sponsored by Protara Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
- 14
- Study locations
NCT06910943: Recruiting Phase 2 study of Liver Injury and Choline Deficiency, sponsored by Protara Therapeutics.
NCT06910943 is a Phase 2 study of Liver Injury and Choline Deficiency that is actively recruiting participants, run by Protara Therapeutics. The registered enrollment target is 129 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 14 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06910943, a Phase 2 study of Liver Injury and Choline Deficiency, is actively recruiting participants, sponsored by Protara Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
- 14
- Study locations
Study Summary
TARA-001-301 is a Phase 2b/3 randomized Open-Label Dose-Selection study with an Open-Label Extension and randomized Double-Blind, Placebo-Controlled Study with Open-Label Extension to investigate the safety and efficacy of Choline Chloride for Injection (Low Dose and High Dose) versus Placebo in adolescents (ages 12 to \< 18 years of age) and adults (≥ 18 years of age) with intestinal failure receiving long-term PS when oral or enteral nutrition is not possible, insufficient, or contraindicated. Participants will be enrolled in one of 2 parts, each part will be followed by an open-label extension period of approximately a year. Part 1: Open-Label Dose-Selection Phase Part 2: Double-Blind, Placebo-Controlled Phase The purpose of the Open-Label Dose-Selection Phase is to evaluate the safety, tolerability, how Choline Chloride for Injection (study drug) is distributed in the body, and to select 2 of 3 doses for testing in the Double-Blind, Placebo-Controlled Phase. The purpose of the Double-Blind, Placebo-Controlled Phase is to assess the safety of the study drug and how well the study drug works at the 2 selected dose levels.
Primary Outcome
Cmax = maximum concentration
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Choline Chloride for Injection
Study Locations (14)
Other
- University Hospitals Leuven, Campus Gasthuisberg - Leuven
- Aalborg University Hospital, Department of Medical Gastroenterology - Aalborg
- Rigshospitalet - University Hospital Copenhagen - Copenhagen
- Beaujon Hospital - APHP - Clichy
- Rennes University Hospital Center - Pontchaillou Site - Rennes
- CHRU Nancy - Barbois Hospital - Vandœuvre-lès-Nancy
- Charite - University Hospital Berlin - Berlin
- University Duisburg-Essen, University Hospital Essen - Essen
- M. Pirogow Provincial Specialized Hospital in Lodz, Nutritional Treatment Center - Lodz
- Czerniakowski Hospital Sp. z o.o. (LCC) - Warsaw
Colorado
- University of Colorado School of Medicine - Aurora
New York
- Columbia University Medical Center/ New York Presbyterian Hospital - New York
North Carolina
- Duke Clinic - Abdominal Transplant Research Office - Durham
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2025-12-10 |
| Est. Completion | 2028-06 |
| Phase | Phase 2 |
What NCT06910943 shows while recruiting
NCT06910943 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 2 conditions, with Liver Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06910943 lists 14 locations in 5 states (Other, Colorado, New York).
Frequently Asked Questions
What is clinical trial NCT06910943 about?
NCT06910943 is a clinical study titled "Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support". TARA-001-301 is a Phase 2b/3 randomized Open-Label Dose-Selection study with an Open-Label Extension and randomized Double-Blind, Placebo-Controlled Study with Open-Label Extension to investigate the safety and efficacy of Choline Chloride for Injection (Low Dose and High Dose) versus Placebo in ado...
What is the current status of trial NCT06910943?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2025-12-10. Estimated completion is 2028-06.
What conditions does trial NCT06910943 study?
This clinical trial studies the following conditions: Liver Injury, Choline Deficiency.
What interventions are being tested in trial NCT06910943?
The interventions under investigation include: Placebo (DRUG), Choline Chloride for Injection (DRUG).
Who is sponsoring clinical trial NCT06910943?
This trial is sponsored by Protara Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06910943 being conducted?
This trial has 14 study locations across Colorado, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06910943's enrollment target sits among peer trials
129 553rd of 2000 higher than 1,448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI